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INTRODUCTION 
Major advances in the detection, treatment, and control of essential hypertension have 
been made since the early 1970's. Studies, such as the Hypertension Detection and 
Follow-up Program and the Framingham Study, have clearly defined the risk of high 
blood pressure for increasing cardiovascular morbidity and mortal i ty . 1^ Further 
controlled clinical trials have shown benefits In treating milder levels of hypertension 
and have redefined the criteria for diagnosing borderline (Diastolic Blood Pressure or 
DBP of 8 5 - 8 9 mm Hg) and mild (DBP of 9 0 - 1 0 4 mm Hg) hypertension. Early detection 
and treatment have reduced the incidence of complications associated with hypertension, 
such as stroke, congestive heart failure, left ventricular hypertrophy, and further 
progression of hypertension.3 - 7 
The majority of these trials utilized the standard stepped care approach as 
recommended by the Joint National Committee (JNC) on Detection, Evaluation, and 
Treatment of High Blood Pressure. ® If nonpharmacologic interventions, such as sodium 
restriction, weight reduction, and alcohol restriction had failed, patients were first 
started on a diuretic or beta-adrenergic blocking agent. Despite early detection and blood 
pressure control, these studies failed to show a decrease In coronary artery events such as 
angina pectoris, myocardial Infarction, and sudden death. All of these events are major 
sequelae of hypertension.3 - 7 The Multiple Risk Factor Intervention Trial (MRFIT) 
actually demonstrated an increase in coronary events in patients on high doses of 
diuretics.7 Disappointing results in these trials which utilized the stepped care approach 
may have been due to the adverse metabolic effects  induced ty diuretics and 
beta-adrenergic blocking agents. There Is evidence that both thiazide diuretics and 
beta-adrenergic blocking agents cause hyperlipidemia.9 Diuretics are also associated 
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with hypokalemia, glucose Intolerance, and hyperuricemia9 These potential adverse 
effects  of diuretics and beta-adrenergic blocking agents, plus the availability of new 
classes of antihypertensive agents, have led to a reassessment of the traditional stepped 
care approach. 
Essential hypertension is a multifactorial disease and no single approach applies to all 
patients. Drug treatment should be individualized based on each patient's profile. 
Physiologic and metabolic factors such as age, race, sex, obesity, sodium intake, 
concurrent disease states, and renin profiling should be considered when tailoring a 
patient's antihypertensive drug regimen. 1 ® 
Studies to date have defined subsets of patients who respond better to specific classes 
of antihypertensive drugs. Elderly patients, blacks, and patients with low plasma renin 
concentrations are more responsive to diuretics or calcium channel blxking agents, while 
younger patients (especially men under 40 years of age) and patients with high plasma 
renin concentrations are more responsive to beta-adrenergic blocking agents or 
angiotensin converting enzyme Inhibitors. 1 1 - 1 8 All hypertensive patients do not have 
the same underlying disease. Despite the heterogeneity of hypertension, calcium appears 
to be a common thread in the regulation of blood pressure. 
Research efforts  have fxused on the role of calcium Ions In the pathophysiology of 
essential hypertension. Calcium plays a key role in the contraction of vascular 
smooth muscle. Calcium also participates in the modulation of sympathetic tone, 
catecholamine release from the adrenal medulla, aldosterone secretion, renin release, 
and myocardial contractility. Calcium ions cross the cell membrane through the open ng 
of slow calcium channels. Calcium ions released from intracellular binding sites also 
contribute to increases in intracellular calcium concentrations. This setting leads to an 
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increase in vascular resistance which is the basic underlying hemodynamic abnormality 
in most patients with chronic hypertension. ' 9 
With this understanding of the relationship between calcium and blood pressure, 
attention has focused on the use of calcium channel blocking agents in the treatment of 
essential h y p e r t e n s i o n . 3 7 Calcium channel blxking agents decrease the calcium 
influx into vascular smooth muscle cells, thus reducing contractility and vascular tone. 3 7 
The vasodllatory effects  of calcium channel blocking agents are enhanced In hypertensive 
patients, but minimal In normotensive patients. The blood pressure lowering effect  of 
these agents depends on the magnitude of pretreatment blood pressure levels. This finding 
reinforces the theory of a calcium-dependent dysregulatlon In essential hypertension. 2 2 • 
3 0 , 3 2 
Calcium channel blxking agents offer  a number of advantages over diuretics, 
beta-adrenergic blxking agents, and other vasodilators. Calcium channel blxking agents 
have been shown to lower blood pressure both at rest and during exercise while 
maintaining blood flow to vital organs. In contrast to calcium channel blxking agents, 
diuretics can cause plasma volume xn t rx t ion which may lead to xmpromised blood flow. 
Fatigue and exercise intolerance are less likely to oxur with calcium channel blxking 
agents than with beta-adrenergic blxking agents. Adverse metabolic effxts  seen with 
diuretics and beta-adrenergic blxking agents have not been enxuntered with calcium 
channel blxking agents. Unlike other vasodilators, calcium channel blxking agents have 
a sustained blood pressure lowering effxt  without causing sodium retention. In fact, 
calcium channel blxking agents exhibit a natriuretic and diuretic effxt  which may be due 
to a drug-induced increase in renal blood flow. 2 8 - 3 0 
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As previously stated, calcium channel blxking agents have a greater antihypertensive 
effect  in elderly patients, blacks, and low-renin patients when compared to 
beta-adrenergic blxking agents. Calcium channel blxking agents can be prescribed in 
disease states where beta-adrenergic blxking agents may be dontraindicated, such as 
asthma, chronic obstructive pulmonary disease, diabetes mellitus, and peripheral 
vascular disease.17 These factors must be considered when individualizing a patient's 
antihypertensive treatment. 
Calcium channel blxking agents are a heterogenous group of compounds which have 
diverse chemical structures and pharmacologic actions. Calcium channel blxking agents 
currently available in the United States include verapamil, nifedipine, and diltiazem. 
These agents have short elimination half-lives and undergo extensive first-pass 
metabolism requiring frequent dosing to maintain the desired therapeutic response. 
Extended-release formulations which can be taken once a day are under investigation for 
diltiazem and nifedipine, while such a preparation for verapamil has recently been 
released. Additional long-xting calcium channel blxking agents are under investigation 
and new generations of calcium channel blxking agents are being developed. 
Nitrendipine is an investigational, dihydropyridine, calcium channel blxking agent, 
structurally related to nifedipine. Nitrendipine was first developed in West Germany in 
1978. It has been used extensively in Europe since the early 1980's for the treatment of 
hypertension. Nitrendipine has been classified as one of the more potent calcium channel 
blxking agents of the dihydropyridine group due to its peripheral vasodilating 
properties,38 
The pharmacologic xtivit ies of nitrendipine compare favorably to other calcium 
channel blxking agents. Nitrendipine is rapidly absorbed following oral administration. 
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The hypotensive effect  of nitrendipine, when given in doses ranging from 5 to 40 mg, is 
seen within 30 minutes after administration, The maximum blood pressure lowering 
effect  occurs between 1 and 3 hours following a dose, and lasts for 8 to 24 hours. The 
major advantage of nitrendipine over other currently available calcium channel blxking 
agents is its long duration of action which allows it to be dosed once or twice daily. 
Nitrendipine is extensively metabolized by the liver. Five metabolites have been isolated, 
each having one thousand times less activity than the parent compound. Approximately 
45$ of a nitrendipine dose is excreted in the urine as polar acidic metabolites. The 
remainder is excreted in the bile, • 
Clinical trials have shown that nitrendipine is effxtive  as monotherapy 4 1 " 4 9 and 
combination therapy 5 0 ~ 5 8 in the treatment of essential hypertension. Studies which 
compared nitrendipine to diuretics or beta-adrenergic blxking agents demonstrated 
similar effxts  in lowering blood pressure. However, patient groups treated with 
nitrendipine had fewer drop outs and fewer reports of adverse e f f x t s 5 2 " 5 4 
Nitrendipine has also been used in combination with diuretics, beta-adrenergic blxking 
agents, and angiotensin xnverting enzyme inhibitors. Studies in which a second agent was 
added to nitrendipine therapy demonstrated a further  dxrease in blood pressure. The 
dose of nitrendipine in these studies has ranged from 10 to 80 mg per day in either a 
single dose or two divided doses.41 " 5 8 Initial trials in Europe used a dose of 20 to 40 mg 
twice a day. More recent studies have used this same dosage range, but have administered 
the dose once a day. Questions surrounding the lowest effxtive  dose of nitrendipine and its 
appropriate dosing interval have yet to be answered. 
Nitrendipine therapy generally has been well tolerated. Stoepel and colleagues 
reported on the safety profile of nitrendipine in 967 patients. Headxhe was the most 
commonly reported side effect,  followed by flushing, ankle edema, palpitations, 
dizziness, and fatigue. No laboratory abnormalities were reported with nitrendipine 
monotherapy.59 
Study Objective 
The purpose of this study was to evaluate the dose response and safety profile of 5 , 10, 
and 20mg of nitrendipine compared to placebo when given once daily in the treatment of 
mild hypertension. The study was also designed to assess the duration of blood pressure 
lowering effxt  following a single daily dose of nitrendipine, This study will help to 
determine the lowest effective dose of nitrendipine and If once dally dosing Is appropriate, 
METHODS 
Study Design 
This study was part of a multlcenter, randomized, double-blind, placebo-controlled, 
parallel trial. The stucty was conducted through the Family Practice Clinic at University 
Hospital, following approval by the Institutional Review Board of the University of Utah. 
Male or female patients, 21 years of age or older, with a history of mild essential 
hypertension were considered for the study. Patients were required to discontinue their 
previous antihypertensive medication. If patients were taking other drugs affecting blood 
pressure that could not be discontinued (i.e. monoamine oxidase inhibitors, sedatives, 
tranquilizers, tricyclic antidepressants, neuroleptic drugs, anorectics, and 
decongestants) they were excluded from the study. 
In addition, patients were excluded if they were known to have labile hypertension, 
impaired renal or iiver function, a history of myocardial infarction in the previous three 
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months, clinical signs of heart failure, evidence of a major arrhythmia or conduction 
disturbance, failure of a major organ system, or severe Infection, malignancy or 
psychosis, Females were required to be postmenopausal or surgically sterilized, All 
patients signed a written Informed consent document (Appendix I) prior to enrollment In 
the study 
All patients entering the study were given placebo (one tablet dally) for the first three 
weeks under single-blind conditions as a washout period, Three seated blood pressures 
were obtained on each weekly visit. For the patient to qualify for the study, the average 
diastolic blood pressure (DBP) from visits three and four had to be > 95mmHg to <105 
mmHg. 
Patients with confirmed mild hypertension were then randomized to one of four 
treatment groups and given nitrendipine or placebo for eight weeks under double-blind 
conditions, The four treatment groups consisted of the following regimens: nitrendipine 
5mg once dally for eight weeks; nitrendipine 5mg once dally for two weeks followed by 
lOmg once dally for six weeks; nitrendipine 5mg once dally for two weeks followed by 
lOmg once dally for two weeks followed by 20mg once dally for four weeks; or placebo 
daily for eight weeks, (See Figure I for randomized treatment groups.) Patients were 
followed In clinic every two weeks during the double-blinded portion of this study, 
Patients were Instructed to take their medication in the early morning, but not on the 
morning of their clinic visit. On the day prior to their clinic visit, they were Instructed 
to take their medication 24 hours before their clinic appointment. No special counseling 
was provided on weight control, reducing salt Intake, or adjusting other dietary factors. 
Clinical Evaluation 
Patients were seen weekly during the placebo period and biweekly upon entry into the 
study Seated blood pressures and heart rates were recorded at all visits. (See Appendix 11 
for a detailed methodology for obtaining these measurements) Three blood pressure 
measurements were taken after patients had been seated for a minimum of five minutes. 
The average of these three blood pressures was then recorded. If at any time during the 
study, a patient's average DBP rose above 115 mm Hg, they were exited from the 
study. 
The first visit consisted of a medical history, a complete physical examination, a 
12-lead electrocardiogram (ECG), and baseline blood pressure and heart rate values. 
A complete physical examination and 12-lead ECG were also performed after three weeks 
on placebo, and upon completion of the stud/. Brief physical examinations were 
performed at all other visits. A baseline chest X-ray was obtained on visit three, unless 
the patient had an available chest X-ray report within the previous six months. 
Patients were questioned in a systematic yet nonspecific manner at each visit about 
possible adverse effects.  All adverse effects  were categorized as being highly probable, 
probable, possible, or remotely related to the study medication. The severity of adverse 
reactions was also defined as mild, moderate, or severe. Patient compliance was also 
assessed at each visit by checking the number of returned tablets. Any discrepancies in 
tablet count were noted. 
Laboratory Studies 
The following laboratory tests were performed after two weeks on placebo (visit 3) 
and upon completion of the eight week double-blind period: Complete blood count (CBC) 
with differential  and platelet count, serum glucose, uric acid, calcium, phosphate, sodium 
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potassium, chloride, creatinine, blood urea nitrogen (BUN), total protein, albumin, 
cholesterol, triglycerides, serum glutamic oxalacetic transaminase (SGOT), serum 
glutamic pyruvate transaminase (SGPT), lactic dehydrogenase (LDH), alkaline 
phosphatase, total bilirubin. Seven milliliters (ml) of blood were collected in a lavender 
top tube for the CBC, and two blood smear slides were prepared from this sample. The 
chemistry panel, serum magnesium, and creatine phosphokinase (CPK) each required 
10ml of blood to be collected in a red top tube. After processing and packaging these blood 
samples in the clinic, they were shipped to SmithKline Bio-Science Laboratories in Van 
Nuys, California for analysis to ensure consistency among the investigational sites. A 
urinalysis was also obtained at visit three and eight, and this included specific gravity, 
pH, glucose, albumin, ketones, and microscopic red blood cell count (RBC) and white blood 
cell count (WBC). The urinalysis was performed by the Associated Regional University 
Pathologists INC. (ARUP), Salt Lake City, Utah. See Table I for a summary of all 
measurements performed in this study. 
Analysis 
Following data collection, descriptive statistics were used for patient demography, 
blood pressure response, and side effect  profile. (See Appendix III for data collection 
form.) Blood pressure response was defined as either a 10 mm Hgdrop in blood pressure 
or an average DBP below 90 mm Hg at the completion of the study. Partial responders did 
not meet these criteria, yet had a consistent decrease in average DBP during the study. 
Nonresponders did not have a consistent decline In DBP, and In some cases the DBP 
increased during the study. Mean blood pressures and standard deviations were calculated 
for each group. Changes from baseline were assessed at the completion of the study for 
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blood pressure, heart rate, and weight. Preliminary results are reported for 15 patients 
who had completed the study by April 30, 1987. The Investigators will remain blinded 
until all patients in this multicenter trial have finished the study.. 
RESULTS 
Sixty-six patients met the Initial entrance criteria and were screened for entry into 
the study. Of these patients, 35 did not qualify for the study either because their average 
DBP from visits two and three was > 105 mm Hg or < 95 mm Hg, or because they 
voluntarily dropped out, Thirty-one patients qualified for the study but five patients did 
not complete the study. One of these patients was exited when her average DBP rose above 
115 mm Hg. One patient was exited by the investigators due to severe headaches while 
on the study medication. The remaining three patients withdrew voluntarily or due to 
illnesses not related to the stud/ medication. These five patients were excluded from the 
blood pressure response analysis, but included in the evaluation of adverse effects.  Of the 
remaining 26 patients, 15 had completed the study as of April 30, 1987. 
Demographic data of the 15 patients who have completed the study are listed in Table 
II based upon their blood pressure response. Six women and nine men completed the 
study; all were caucaslan. The majority of responders were female ( 4 / 6 ) , while the 
majority of nonresponders were male ( 6 / 7 ) , The two partial responders consisted of one 
male and one female. Nonresponders tended to weigh more than the other two groups upon 
entry into the study. All three groups had a slight decrease in weight during the study, 
\ 
although these changes were not clinically significant. See Table 4, section D, for a 
summary of these weight changes. 
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Other variables such as age, height, duration of hypertension, and baseline blood 
pressures and heart rates were similar among the three groups. All patients, except for 
the two partial responders, had been on antihypertensive medications prior to enrollment 
In this study. One patient continued to smoke during the study and he was In the 
nonresponslve group. No patients in the study drank alcohol excessively. All patients 
were compliant with their study medication based .on tablet counts at each visit. 
Average systolic and diastolic blood pressures, along with heart rates, are plotted for 
each patient in Figures 2 through 16. When patients were grouped by response, results 
showed that the mean DBP dropped from 96 +_ 1 to 85 +. 4 (mean +. standard deviation) In 
the responsive group. This represented an 11 mm Hg reduction in mean DBP. Partial 
responders had a 6 mm Hg reduction, while nonresponders had a 2mmHg increase in 
mean DBP. (See Table 4, Section A.) All three groups had a decrease in mean SBP. 
Responders had a 14 mm Hg reduction; partial responders had a 7 mm Hg reduction; and 
nonresponders had a 4 mm Hg reduction In SBP. (See Table 4, Section B.) Nonresponders 
had a very slight increase in heart rate, while partial responders had a slight decrease in 
heart rate, Responders had a 7 beats per minute (bpm) Increase In heart rate, going from 
an average of 74 ± 7 to 81 ± 6 . (See Table 4 , Section C, for heart rate changes.) 
Adverse effects  which the Investigators classified as either possibly or probably 
related to the study medication are listed In Table 3. The total number of patients 
evaluated In each group for side effects  is Indicated In the table. Two out of the twenty 
patients evaluated reported no adverse reactions. One patient dropped out of the stud/ due 
to severe headaches. No other drop-outs were due to adverse reactions from the study 
medication. Headaches and edema were the most frequently reported adverse effects  in the 
study. One patient in the responding group developed a maculopapular rash, but this 
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resolved while continuing treatment. Another patient in the responding group 
experienced facial flushing approximately 30 minutes after each dose and this lasted for 
several hours. This flushing continued throughout the study. Another patient in the 
responding group experienced urinary frequency while on the study medication which may 
have been due to the reported diuretic effect  of calcium channel blxking agents. A urine 
culture was performed on this patient which ruled out infection. Two patients In the 
nonresponding group experienced ECG changes during the stud/. One patient developed 
first degree heart b lxk during the xurse of the study. The second patient had new ST-T 
wave changes at the xmpletion of the study, but CPK levels were normal. A cardiology 
consultation was obtained on this patient and It was determined that the ST-T wave changes 
may have been due to left ventricular hypertrophy secondary to hypertension, It was also 
discovered that this patient had an Intermittent, rate-related, left bundle branch blxk. 
No clinically significant changes or abnormalities in laboratory tests were noted during 
the stud/. 
At the xmpletion of the study, patients were asked to xmpare the study medication to 
their prior antihypertensive regimen. Three patients stated the study medication was 
"better" than their prior treatment; four patients rated the study medication "worse" 
than their prior treatment; six patients said the treatments were "the same;" and two 
patients were not on prior antihypertensive medication. 
DISCUSSION 
The objxtives of this randomized, double-blind, placebo-xntrolled, parallel trial 
were to determine the efficacy,  safety, and lowest effxtive  dose of nitrendipine when dosed 
once a day for the treatment of mild essential hypertension. Since this study has yet to be 
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unblinded, the efficacy and dosage range of nitrendipine in this study cannot be assessed, 
Safety and factors surrounding blood pressure response will be addressed. 
The screening process of this study highlighted some interesting findings that have 
previously been reported in the literature. Sixty-six patients were screened in order to 
obtain a stud/ sample of thirty-one patients. The majority of patients who did not qualify 
for the study had previously been on diuretics for many years. Even though these patients 
had documented histories of essential hypertension, they remained normotensive following 
the three week single-blind placebo washout period. Several studies have demonstrated 
that hypertensive patients controlled on diuretics alone can take extended "drug holidays" 
for up to two years before hypertension recurs, 6 0 - 6 2 
Patients in this study who were on prior diuretic therapy also experienced a high 
incidence of edema during the washout period, This has previously been reported 
following abrupt cessation of thiazide diuretics, From this finding, one may ask the 
question of whether edema reported during the stud/ was due to the stud/ medication or to 
withdrawal of prior diuretic therapy. Of the seven patients reporting edema during the 
stud/, six patients were on prior diuretic therapy and one patient was previously on 
enalapril. Three of the six patients on prior diuretic therapy did not report edema until 
the final visit. Later reports may have been due to the study medication, while reports 
earlier in the stud/ may have been a carry-over from discontinued diuretic therapy. 
Peripheral edema has been reported with nitrendipine, but is usually transient. This 
edema has not been associated with weight gain, and in many cases weight has slightly 
decreased, as seen in this study. Natriuresis has either increased or remained the same, 
while volume expansion has not been evident. This suggests that peripheral edema is not 
due to sodium and water retention, as seen with other vasodilators. The predominant effect 
14 
of nitrendipine Is arteriolar vasodilation, while venous dilation Is minimal. This 
imbalance may lead to increased capillary pressure and transudation of fluid to the 
capillaries. 46 ,49 ,50 ,52 
The majority of side effects  reported with nitrendipine are attributable to its 
vasodilatory effects.  Headaches are the most commonly reported side effect,  but are 
usually mild and diminish with continued t h e r a p y 5 9 However, one patient in this study 
was exited due to severe, persistent headaches. Palpitations were reported by one patient 
in this study who had a good blood pressure lowering response, along with an 8 bpm 
increase in heart rate. Increases in heart rate with nitrendipine have been reported, 
especially during the Initial weeks of treatment. This Increase In heart rate is probably 
due toTeflex sympathetic stimulation, which declines with continued treatment due to a 
resetting of the baroreceptors.59 
The majority of patients who entered the study tolerated the study medication well, 
even though It Is unknown If the patient received active drug or placebo. Side effects  were 
reported as mild to moderate, with the exception of the patient who was exited due to 
severe headaches. Approximately 5 0 $ of the patients showed a blood pressure lowering 
response. This may theoretically represent those patients who were randomized to the 
treatment groups that received 10 or 20 mg of nitrendipine, while nonresponders may 
have been In the placebo group or the group that received 5 mg of nitrendipine throughout 
the study. Nitrendipine doses of 5 mg daily have not been studied In the available 
literature, while doses of 5 mg twice daily have not demonstrated consistent 
e f f i c a c y . 5 0 " 5 3 
Many factors may have influenced the blood pressure response in this study, in 
addition to the speculation about patient randomization to treatment groups. Kaplan 
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demonstrated that blood pressure may be elevated under new circumstances and then 
decrease with repeated measures as the patient becomes more comfortable in a particular 
setting. 6 4 In this stud/, patients came to clinic eight times over 11 weeks and usually 
saw the same physician, at the same time on each visit. Repeated blood pressure 
measurements were performed at each visit and this became a "routine procedure." 
Dietary factors may also play a role In blood pressure response. Salt Intake has been 
shown to enhance the antihypertensive effects  of calcium channel blxking agents. Sodium 
loading dxreases plasma renin activity and lowers ionized serum calcium while 
increasing intracellular calcium x n c e n t r a t i o n s . 2 4 " 2 7 This setting favors the 
mxhanism of xtion of calcium channel blxking agents. The effxts  of calcium channel 
blxking agents are less evident when sodium is restricted. 
It is interesting that epidemiologic studies have found no correlation between sodium 
intake and blood p r e s s u r e . 6 6 " 6 8 However, the National Health and Nutrition Survey did 
find an inverse relationship between blood pressure and dietary calcium intake. 6 8 
Pxple with higher blood pressures tended to have a lower calcium intake, and 
supplementation with calcium resulted in lower blood pressures, espxially in patients 
with low renin xncentrations. Resnick and x l l e a g u e s 2 4 - 2 7 have done extensive work in 
the area of calcium metabolism and its link to the renin-anglotensin-aldosterone (RAA) 
system. They have found that low-renin hypertensive patients tend to have changes in 
their calcium-regulating hormones (i.e. parathyroid hormone, calcitonin, and 
1,25-dihydroxy vitamin D) that are xnsistent with calcium deficiency, while 
high-renin patients have a profile which indicates calcium excess. They found that 
patients respond differently  to salt loading or to calcium supplementation depending upon 
their renin profile. Further research is necessary in this area to define the relationships 
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between calcium metabolism, sodium intake, renin concentrations, and blood pressure 
response. 
Patient characteristics that may be helpful in determining blood pressure response 
include age, weight, sex, and race. Despite little difference  in age seen among groups in 
this study, age nevertheless is a useful predictor of response to calcium channel blockers. 
Older patients, especially those over 60 , generally have a sustained decrease in blood 
pressure when treated with calcium channel blockers. This response is related to a 
number of mechanisms. Elderly patients have a reduced baroreflex sensitivity so they 
experience less reflex stimulation following arterial vasodilation. Vascular changes occur 
with age, and vessels become more rigid and less responsive to sympathetic stimulation. 
Plasma renin activity and renal blood flow decrease with age, which leads to a low renin 
state. 6 9 These events provide a good environment in which calcium channel blockers can 
exert their effect. 
Bod/ composition changes with increasing age. Nonresponders In this stud/ tended to be 
elderly and obese, and this may have blunted their blood pressure response. One possible 
explanation which has not been reported in the literature may be related to the lipid 
solubility of nitrendipine.39 Nitrendipine may have been unable to exert its 
antihypertensive effect  due to an increase in volume of distribution and deposition Into 
adipose tissue. A second explanation may be that obesity was an uncorrected risk factor 
for hypertension during the study. 
Differences  in sex and race also play a role in determining blood pressure response. 
It has been reported in the literature that black patients have a greater intravascular 
volume and lower plasma renin activity than white patients. 1 4 , 7 0 However, no black 
patients were in this study, so differences  cannot be assessed. It has been demonstrated 
that men have a greater degree of intravascular volume contraction and a higher total 
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peripheral resistance than women, Women tend to have a better response to calcium 
channel blocking agents than men, although this difference  is minimal . 7 0 Another 
contributing factor may be that women tend to have lower serum calcium concentrations 
as they grow older and this has been associated with low renin states. The majority of 
responders in this stud/ were postmenopausal women, but the patient sample was small 
and other factors could have contributed to this result. 
Patients were polled at the conclusion of the study to determine their opinion of the 
stud/ medication. Their responses were very Interesting and showed how perceptive 
patients can be about their medication. Several patients stated that the once daily dosing 
regimen was preferable to multiple dally doses of their former medication, One patient 
liked the convenience of the study medication, but realized it did not offer  good blood 
pressure control in his case. Another patient stated that the study medication controlled 
her blood pressure better than her previous medication, but she experienced more side 
effects  during the study which was a deterrence to compliance. This demonstrated that 
patient opinion not only reflects safety and efficacy,  but may be a predictor of compliance 
as well. These responses call attention to the following factors that should be considered 
when determining first-line agents in the treatment of hypertension: efficacy,  side 
effects,  patient compliance, frequency and ease of administration, cost, laboratory 
monitoring, potential drug interactions with other agents, and concurrent disease states. 
The role of nitrendipine in first-line therapy can be assessed by using the above 
criteria, Nitrendipine has demonstrated efficacy and safety in the treatment of mild 
essential hypertension, Side effects  are usually well tolerated and transient, This Is an 
important factor when one considers that mild hypertension is an asymptomatic disease. 
Adverse reactions could impair the quality of life and lead to patient noncompliance. 
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Nitrendipine was dosed once daily in this study and patients agreed that this was a 
convenient dosing schedule. Frequent laboratory monitoring is not necessary with 
nitrendipine monotherapy and no laboratory abnormalities have been encountered. 
Additional antihypertensive medications have safely been used with nitrendipine therapy. 
Caution should be used when adding nitrendipine to chronic digoxin therapy, since 
nitrendipine has the potential to increase serum digoxin concentrations.17 Drugs which 
are extensively metabolized by the liver through the P - 4 5 0 enzyme system may compete 
with nitrendipine for metabolism.39 Dosage adjustments may be necessary under these 
circumstances, and also when liver function is severely impaired. The prohibitive factor 
of calcium channel blocking agents when compared to diuretics or beta-adrenergic 
blocking agents is cost. However, calcium channel blxking agents may prove to be 
cost-effxtive  in the presence of other disease states which respond to these agents. For 
example, a calcium channel blxking agent could be the drug of choice in patients with both 
hypertension and xronary artery disease. 
CONCLUSIONS 
In summary, the dose response and duration of xtion could not be assessed in this 
study since this multlcenter trial has not yet been unbllnded. Only one serious side effxt 
was reported from the four treatment groups, and most patients tolerated the stucfy 
medication well. Approximately 5 0 $ of the patients had a blood pressure lowering 
response. This response may have been dependent upon the dose of nitrendipine if these 
patients were receiving x t ive drug. Other fxtors which may have influenced response 
include familiarity with clinic procedures as the study progressed, dietary effxts  on 
blood pressure that were not control led in the study, and patient characteristics such as 
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age, sex, weight, duration of hypertension, and prior antihypertensive treatment. Patient 
opinion of the stud/ medication helped to assess efficacy,  safety, and patient compliance 
Issues. 
The ideal antihypertensive drug is still not available. However, our armamentarium 
continues to grow as better agents are developed. It Is Important to individualize patient 
care in order to achieve the best possible balance between efficacy,  side effects,  and 
patient compliance. Calcium channel blxking agents provide a new approxh to the 
treatment of essential hypertension, but their place in treatment must still be defined. 

T a b l e 1 . M e a s u r e m e n t s p e r f o r m e d d u r i n g t h e s t u d g 
P r o c e d u r e o r E v a l u a t i o n 
V i s i t N u m b e r 
1 2 3 4 5 6 7 8 
M e d i c a l & d r u g h i s t o r y X * 
C o m p l e t e P h y s i c a l X X X 
B r i e f P h y s i c a l X X X X X 
E l e c t r o c a r d i o g r a m ( 1 2 - l e a d ) X X X 
Chest X - r a y X 
L a b o r a t o r y e v a l u a t i o n 
( C h e m 2 0 , C B C , C P K , & U A ) X X 
Assessment o f c o m p l i a n c e X X X X X X X 
S ide e f f e c t  assessment X X X X X X X 
W e i g h t ( i n pounds) X X X X X X X X 
Blood p r e s s u r e & h e a r t r a t e X X X X X X X X 
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Table 2. Patient demographic data based on response 
Responders Partial Responders Nonresponders 





























Wt. corrected for 
body surface area 




(beats per minute) 
6 0 + . 15 
64 + 5 
176 ± 3 8 
165 
1 2 ± 12 
74 + 7 
Baseline BP (mm Hg) 
Systolic 1 4 4 + 1 2 
Diastolic 96 + 1 
48 ± 13 
66 ± 4 
1 5 8 ± 9 
161 
8 +. 9 
80 + 6 
137 + 0 
98 + 2 
5 8 + 9 
69 ± 4 
200 ± 2 0 
183 
13 12 
8 2 ± 12 
150 + 20 
98 + 3 
Note: Values reported as mean +_ standard deviation 
23 
Table 3. Number of patients reporting adverse effects* 
Responders Partial Nonresponders Drop-
( n = 6 ) Responders ( n = 7 ) Outs 











Urinary Frequency 1 
ECG changes: 
First degree 
heart block 0 
ST-T wave changes 0 
1 4 1 
0 2 1 
0 2 0 
0 0 0 
0 0 1 
0 0 0 
0 0 0 
0 0 0 
0 0 1 
0 0 0 
0 0 0 
0 1 0 
0 1 0 
* Mult iple side effects  may be reported by a single patient 
Table 4. Measured changes during the study 
Responders Partial Responders Nonresponders 
( n = 6 ) ( n = 2 ) ( n = 7 ) 
A. Diastolic Blood Pressure 
(DBP) in mm Hg 
entry 
completion 
96 + 1 
85 ± 4 
98 + 2 
92 ± 1 
98 + 3 
100 ± 5 
change in DBP - 1 1 - 6 + 2 
B. Systolic Blood Pressure 
(SBP) In mm Hg 
entry 
completion 
144 + 12 
130 ± 9 
137 + 0 
130 + 2 
150 + 20 
146 ± 13 
change in SBP - 1 4 - 7 - 4 
C. Heart r a t e ( H R ) 
In beats per minute 
entry 
completion 
7 4 + 7 
81 ± 6 
8 0 + 6 
76 + .11 
8 2 + 12 
83 + .11 
change In HR + 7 - 4 + 1 
D. Weight ( l b s ) 
entry 
completion 
176 + 38 
172 + 36 
158 v 9 
155 ± 7 
2 0 0 + 2 0 
199 ± 2 5 
change In wt. - 4 - 3 - 1 
• 
S 3 M 9 I J 
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Placebo 
x 8 weeks 
Figure 1. Pat ient Randomization. Twenty pat ients met the entrance 
c r i t e r i a of the study and were randomized to one of these 
four t rea tment groups dur ing t h i s p r e l i m i n a r y t r i a l . 





-o- Heart Rat 
Visit no. 
Figure 2 . Plot of average systolic and diastolic 
blood pressure, along v i t h heart ra te , 
over eight c l in ic v i s i t s for patient * \ 




-a- Heart Rate 
Visit no. 
Figure 3 . Plot of average systolic and diastol ic 
blood pressure, along w i t h heart r a t e , 
over eight c l in ic v is i ts for patient 




o - Heart Rate 
Yis i t no. 
Figure 4 . Plot of average systolic and diastolic 
blood pressure, along w i t h heart ra te , 
over eight c l in ic v i s i t s for patient * 4 




- • - Diastolic 
- o Heart Rate 
Visit no. 
Figure 5 . Plot of average systol ic and diastol ic 
blood pressure , along v i t h heart ra te , 
over eight c l in ic v is i ts for patient * 6 






-o- Heart Rate 
Visit no. 
Figure 6 . Plot of average systolic and diastolic 
blood pressure, along v i t h heart r a t e , 
ever eight c l in ic v is i ts for patient * 1 





-o- Heart Rate 
Visit no. 
Figure 7 . Plot of average systol ic and diastolic 
blood pressure, along v i t h heart r a t e , 
over eight c l in ic v i s i t s for patient * 9 





-Q- Heart Rate 
Figure 8 . Plot of average systol ic and diastol ic 
bleod pressure, along v i t h heart ra te , 
over eight c l in ic v i s i t s for patient * 1 0 





-o- Heart Rate 
Visit no. 
Figure 9 . Plot of average systolic and diastolic 
blood pressure, along v i t h heart ra te , 
over eight c l in ic v is i ts for patient * \ 1 






Figure 10 . Plot of average systol ic and diastolic 
blood pressure, along v i t h heart ra te , 
over eight c l in ic v is i ts for patient * 1 3 






-o- Heart Rate 
Figure 11 . Plot of average systol ic and diastolic 
blood pressure , along v i t h heart ra te , 
over eight c l in ic v i s i t s for patient * 1 4 





-a- Heart Rate 
Figure 12 . Plot of average systol ic and diastolic 
blood pressure , along v i t h heart ra te , 
over eight c l in ic v i s i t s for patient * 1 5 






-o- Heart Rate 
Figure 13 . Plot of average systol ic and diastolic 
blood pressure, along v i t h heart r a t e , 
over eight c l in ic v i s i t s for patient * 1 6 
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Figure 14 . Plot of overage systol ic and diastolic 
blood pressure , along v i t h heart ra te , 
over eight c l in ic v i s i t s for patient * 1 7 





-o- Heart Rate 
Figure 15 . Plot of average systolic and diastolic 
blood pressure , along v i t h heart r a t e , 
over eight c l in ic v i s i t s for patient * \ 8 





-o- Heart Rate 
Figure 16 . Plet of average systol ic and diastol ic 
blood pressure , along v i t h heart ra te , 
over eight c l in ic v is i ts for patient * 1 9 
This patient v a s a nonresponder. 
I XldNBddV 
. . M 
APPENDIX I 43 
Consent Form 
A DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL OF NITRENDIPINE GIVEN 
ONCE DAILY IN HYPERTENSIVE PATIENTS 
Background Information: Nitrendipine Is an Investigational calcium channel blxking drug 
that has a long duration of xt ion and can be given once daily. It has been used 
experimentally in the treatment of hypertension (high blood pressure). This research 
study will test the efficacy and safety of nitrendipine (an Investigational drug) in patients 
with mild essential hypertension. 
Study description: Patients who have mild essential hypertension but are otherwise 
healthy will be asked to participate in the study. You will receive either nitrendipine or 
placebo (an Inactive medication) during the study. You have a 75SB chance of rxelvlng 
nitredipine. The study will last 11 weeks. You will be asked to x m e to clinic every week 
for 4 weeks then every other week to get your blood pressure 8nd heart rate measured. 
The first three weeks of the study Is a screening period. We will determine If your 
diastolic blood pressure Is between 95 and 105. If It Is you will be asked to xntlnue In 
the study for an additional 8 weeks. 
There will be 4 different  treatment groups In this trial. One group of patients will 
receive placebo. The other three groups will rexlve nitrendipine In 3 different  doses. 
Neither you nor the Investigators will know which medication you receive. However, In 
case of an emergency, it Is possible to find out from the sponsor (Miles Pharmaceuticals) 
which medication and dose you are receiving. During the study you will recsive 3 xmplete 
history and physical examinations. You will also receive 3 elxtrocardiograms (painless 
elxtrical tracings of your heart) and one chest X-ray. We will also ask you for 2 urine 
spximens and will draw blood out of your arm vein twice for routine laboratory tests. 
The total amount of blood drawn will be approximately two ounces. 
Possible side effxts  or risks: The following side effxts  have been reported with 
nitrendipine: increased heart rate, headxhe, edema (swelling), palpitations, flushing or 
pallor, dizziness and fatigue. You may also have minor bleeding, bruising, swelling, 
Inflammation or Infxtlon at the site where your blood Is withdrawn. We will discontinue 
the drug if we believe it Is causing a severe side effxt. 
The risk of stopping your blood pressure medication for a short period of time is that your 
blood pressure may increase. If you receive placebo, your blood pressure may be elevated 
for 12 weeks. Such increases for such a short period of time should not cause any 
problem. If your blood pressure gets t x high, you will be dropped from the study and 
treated with medication. 
Potential benefits: The potential benefit to you for participating In this projxt will be the 
possibility of receiving a medication ( I f you are randomized to receive nitrendipine) that 
may help lower your blood pressure. If you are randomized to placebo, there will be no 
d l r x t benefit to you; however the results of this study will help us learn If this drug will 
be useful for other patients with high blood pressure. In addition, you will receive $10 
for exh clinic visit (up to $100 maximum) to help cover the expense of driving to the 
hospital. 
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Alternative treatments: There are many medications that are used to treat high blood 
pressure. If you decide to discontinue your participation, or If your blood pressure Is too 
high during the study, you may receive another medication. 
Confidentiality: The medical Information gathered from this stud/ will be submitted to the 
company funding the project (Miles Pharmaceuticals) and the Food and Drug 
Administration. Participants In the study will be identified by Initials and numbers only. 
Names of participants or material identifying participants will not be released without 
written permission except as such release is required by law. 
If you have any questions about this research project you may contact Dr Jean Nappl 
( 5 8 2 - 1 5 6 5 beeper * 2 9 3 ) 24 hours a day. If you have a question or problem that you do 
not feel comfortable discussing with the Investigator, you may call the Institutional 
Review Board at 5 8 1 - 3 6 5 5 . 
Your participation in this research project is entirely voluntary. You may discontinue 
your participation at any time. If you decide to withdraw your consent, you will receive 
the best care available without prejudice. Your care is in no way contingent upon your 
participation in this stud/. 
Medical treatment or compensation for iniurv: In the event you sustain injury resulting 
from the research project in which you are participating, the University of Utah will 
provide you, without charge, emergency and temporary medical treatment not otherwise 
covered by insurance. Furthermore, if your injuries are caused by negligent acts or 
omissions of University employees acting In the course and scope of their employment, the 
University may be liable, subject to limitations prescribed by law, for additional medical 
costs and other damages you sustain. If you believe that you have suffered  an Injury as a 
result of participation in this research program, please contact the Office  of the Vice 
President for Research, phone number 5 8 1 - 7 2 3 6 . 
A copy of this consent form will be given to you. 
Your signature Indicates you understand the Information provided In this document and all 
your questions have been answered to your satisfaction. 
patient signature Investigator signature 
dote 
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APPENDIX I I 
Methodology for Measuring 
Blood Pressure and Hoart Rate 
The following Is a detailed methodology for the measurement parameters used to assess 
efficacy in this study. 
1. The patient should be located In a quiet, warm setting during all pressure and heart 
rate measurements. All pressures will be recorded using the patient's nondomlnant arm, 
preferably by the same person with the same calibrated mercury sphygmomanometer. 
The observer recording the pressure should be at eye level with the meniscus of the 
mercury column to assure an accurate reading. The appropriate size cuff  will be used for 
each Individual patient. (The bladder should encircle and cover two-thirds of the length of 
the upper arm.) The deflated cuff  should be applied with the lower margin about 2.5 cm 
above the antecubltal space, with the bladder over the Inner aspect of the arm. The 
stethoscope head should be placed firmly (but with as little pressure as possible) on the 
antecubital space over the brachial artery with no space between the skin and the 
stethoscope. The stethoscope should not touch any clothing or the pressure cuff.  With the 
stethoscope in place, inflate the bladder quickly to 30 mm Hg above the point at which the 
radial pulse disappears, and then deflate at a rate of 2 to 3 mm Hg per second. Korotkoff  s 
1st and 5th sounds will be used as determinates of systolic and diastolic pressures, 
respectively. The 1 st sound Is the point at which the Initial tapping sound occurs when all 
previous sounds become inaudible. Pressures will be repeated two more times and the 
average of the three blood pressures will be recorded. 
2 . The heart rate will be determined one time between pressure measurements by 
counting the radial pulse of the nondomlnant arm for 30 seconds and multiplying by two. 
APPENDIX I I I 
APPENDIX I I I 
DATA COLLECTION SHEET 
Patient initials: Race: Caucasian 
Patient number* B lack 
Hispanic 
Sex: male or female Oriental 
Other 
Age: 




B. Diuretic Baseline Blood Pressure (mm Hg) 
C. Beta-blocker SBP: 
D ACE inhibitor DBP: 










Investigator's assessment of study medication 
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